Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Common Equity (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Common Equity data on record, last reported at -$205.3 million in Q4 2025.

  • For Q4 2025, Common Equity rose 81.3% year-over-year to -$205.3 million; the TTM value through Dec 2025 reached -$205.3 million, up 81.3%, while the annual FY2025 figure was -$205.3 million, 81.3% up from the prior year.
  • Common Equity reached -$205.3 million in Q4 2025 per PTCT's latest filing, down from -$155.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $292.6 million in Q1 2021 and bottomed at -$1.1 billion in Q4 2024.
  • Average Common Equity over 5 years is -$377.9 million, with a median of -$216.7 million recorded in 2022.
  • Peak YoY movement for Common Equity: plummeted 24236.72% in 2022, then skyrocketed 85.23% in 2025.
  • A 5-year view of Common Equity shows it stood at $1.4 million in 2021, then tumbled by 24236.72% to -$347.1 million in 2022, then plummeted by 135.84% to -$818.6 million in 2023, then plummeted by 34.15% to -$1.1 billion in 2024, then soared by 81.3% to -$205.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$205.3 million in Q4 2025, -$155.8 million in Q3 2025, and -$206.5 million in Q2 2025.